Document is current
Any future updates will be listed below
-
Authors
Carrasquillo, Jorge A.
O’Donoghue, Joseph A.
Beylergil, Volkan
Ruan, Shutian
Pandit-Taskar, Neeta
Larson, Steven M.
Smith-Jones, Peter M.
Lyashchenko, Serge K.
Ohishi, Norihisa
Ohtomo, Toshihiko
Abou-Alfa, Ghassan K.
-
Funding
Funding for this research was provided by:
Chugai Pharmaceutical
F. Hoffmann-La Roche
National Cancer Institute (P30 CA008748)
Ludwig Institute for Cancer Research
- License Information
-
More Information
Article History
Received: 11 December 2017
Accepted: 22 February 2018
First Online: 5 March 2018
Ethics approval and consent to participate
: This study was reviewed and approved by MSK’s IRB, and all patients provided verbal and written informed consent.
: N/A.
: Two authors, Norihisa Ohishi and Toshihiko Ohtomo, are members of Chugai Pharmaceutical Co., Ltd. The rights to the antibody are held by Hoffmann-La Roche, Inc., which funded the trial. The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
